Mouth-heart axis: Contribution of oral dysbiotic bacteria in the initiation and development of cardiovascular conditions
DOI:
https://doi.org/10.66585/ohmi.2025.1.0006Schlagwörter:
Bacteremia, Infective endocarditis, Inflammation, Mouth-heart axis, Oral dysbiosis, Oral microbiome, Periodontal pathogensAbstract
The oral microbiota begins to establish at birth and develops over time under the influence of genetic factors, environmental exposures, diet, and individual oral health behaviors. In a healthy state, these microorganisms exist in a balanced ecosystem; however, disruption of this balance, known as oral dysbiosis, can promote oral diseases such as dental caries and periodontitis (PD). Growing scientific evidence indicates that the impact of oral microbial imbalance may extend beyond the oral cavity. With advances in molecular detection techniques, oral bacterial species have been identified in distant body sites, including heart valves, suggesting a possible association between oral dysbiosis and cardiovascular disease. Chronic periodontal inflammation and microbial imbalance may allow bacteria or their inflammatory products to enter the bloodstream, leading to bacteremia via direct invasion or immune-mediated mechanisms. These processes may contribute to systemic inflammation and potentially influence the development and progression of cardiovascular disease. This study aims to review and summarize current evidence on the relationship between oral dysbiosis and cardiovascular disease, with particular focus on the mechanisms by which chronic oral inflammation and microbial imbalance may contribute to bacteremia and systemic inflammatory pathways that influence cardiovascular health.
Literaturhinweise
1. Zhen W, Wang Z, Wang Q, Sun W, Wang R, Zhang W, et al. Cardiovascular disease therapeutics via engineered oral microbiota: Applications and perspective. iMeta. 2024;3(3):197. https://doi.org
/10.1002/imt2.197
2. Chopra A, Franco-Duarte R, Rajagopal A, Choowong P, Soares P, Rito T, et al. Exploring the presence of oral bacteria in non-oral sites of patients with cardiovascular diseases using whole metagenomic data. Sci Rep. 2024;14(1):1476. https://doi.org/10.1038/s41598-023-50891-x
3. Talapko J, Juzbašić M, Meštrović T, Matijević T, Mesarić D, Katalinić D, et al. Aggregatibacter actinomycetemcomitans: From the oral cavity to the heart valves. Microorganisms. 2024;12(7):1451. https://doi.org/10.3390/microorganisms12071451
4. Qin H, Li G, Xu X, Zhang C, Zhong W, Xu S, et al. The role of oral microbiome in periodontitis under diabetes mellitus. J Oral Microbiol. 2022;14(1):2078031. https://doi.org/10.1080/2000229
7.2022.2078031
5. Rosier BT, Marsh PD, Mira A. Resilience of the oral microbiota in health: Mechanisms that prevent dysbiosis. J Dent Res. 2018;97(4):371-380. https://doi.org/10.1177/0022034517742139
6. Park S-Y, Hwang B-O, Lim M, Ok S-H, Lee S-K, Chun K-S, et al. Oral-gut microbiome axis in gastrointestinal disease and cancer. Cancers. 2021;13(9):2124. https://doi.org/10.3390/cancers13092124
7. Leng Y, Hu Q, Ling Q, Yao X, Liu M, Chen J, et al. Periodontal disease is associated with the risk of cardiovascular disease independent of sex: A meta-analysis. Front Cardiovasc Med. 2023;10:1114927. https://doi.org/10.3389/fcvm.2023.1114927
8. Taymour N, Ali MAM, Taher ES, Atia GA, Abdeen A, Chaudhary AA, et al. Functionalized nanodiamonds in dentistry: Multifunctional frontiers for oral and maxillofacial regeneration. J Drug Deliv Sci Technol. 2025;114:107448. https://doi.org/10.1016/j.jddst.2025.1
07448
9. Atia GA, Abdal Dayem A, Taher ES, Alghonemy WY, Cho SG, Aldarmahi AA, et al. Urine-derived stem cells: A sustainable resource for advancing personalized medicine and dental regeneration. Front Bioeng Biotechnol. 2025;13:1571066. https://doi.org/10.3389/fbio
e.2025.1571066
10. Costa RHSD, Pessoa RT, Silva EDS, Araujo IM, Gonçalves SA, Rocha JE, et al. Antibacterial and inhibitory activity of Nora and Mepa efflux pumps of estragole complexed to β-cyclodextrin (ES/β-CD) in vitro against Staphylococcus aureus bacteria, molecular docking and MPO-based pharmacokinetics prediction. Pharmaceutics. 2024;16(11):1469. https://doi.org/10.3390/pharmaceutics161114
69
11. Chew RJJ, Tang YL, Lin XYS, Oh FJB, Sim RP, Anwar EJ, et al. Toll-like receptor-4 activation by subgingival biofilm and periodontal treatment response. Clin Oral Investig. 2023;27(5):2139-2147. https://doi.org/10.1007/s00784-023-04877-8
12. Taymour N, Alkandari M, Alkandari M, Haque MA, El Arabi MA, Atia GAN, et al. Oral stem cells in combination with hydrogels as biomimetic bioactive platforms for periodontal tissue engineering. Front Oral Health. 2026;6:1740392. https://doi.org/10.3389/froh.
2025.1740392
13. Atia GAN, Ali MAM, Abdeen A, Alghonemy WY, Elsayed AZ, Shaban E, et al. Recombinant biologics in periodontal and peri-implant reconstruction: Advances, delivery strategies, and translational challenges. J Drug Deliv Sci Technol. 2026;119:108140. https://doi.org/10.1016/j.jddst.2026.108140
14. Westmeier D, Siemer S, Vallet C, Steinmann J, Docter D, Buer J, et al. Boosting nanotoxicity to combat multidrug-resistant bacteria in pathophysiological environments. Nanoscale Adv. 2020;2(11):5428-5440. https://doi.org/10.1039/D0NA00644K
15. Alkandari M, Barai P, Atia GAN, Mohamed SZ, Ghobashy MM, Shalaby HK, et al. Bioactive functionalized chitosan thermo-responsive hydrogels as promising platforms for therapeutic, regenerative oral, and maxillofacial applications. Biotechnol J. 2025;20(1):e202400653. https://doi.org/10.1002/biot.202400653
16. Pipicz M, Kocsis GF, Sárváry-Arantes L, Bencsik P, Varga ZV, Ferdinandy P, et al. Low-dose endotoxin induces late preconditioning, increases peroxynitrite formation, and activates STAT3 in the rat heart. Molecules. 2017;22(3):433. https://doi.org/
10.3390/molecules22030433
17. Wang Z, Bao J, Yang Y, Wei Y, Li C, Pan Y, et al. The impact of periodontitis on cardiovascular disease: Mechanisms, evidence, and therapeutic implications. Int J Dent. 2025;2025:3694736. https://doi.org/10.1155/ijod/3694736
18. Szekely Y, Arbel Y. A review of interleukin-1 in heart disease: Where do we stand today? Cardiol Ther. 2018;7(1):25-44. https://doi.org/1
0.1007/s40119-018-0104-3
19. Mehta NN, deGoma E, Shapiro MD. IL-6 and cardiovascular risk: A narrative review. Curr Atheroscler Rep. 2024;27(1):12. https://doi.org/10.1007/s11883-024-01259-7
20. Shrivastava AK, Singh HV, Raizada A, Singh SK. C-reactive protein, inflammation and coronary heart disease. Egypt Heart J. 2015;67(2):89-97. https://doi.org/10.1016/j.ehj.2014.11.005
21. Lonardo A. The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: A narrative review focusing on principal risk modifiers. Expert Rev Clin Pharmacol. 2023;16(10):891-911. https://doi.org/10.1080/17
512433.2023.2259306
22. Mivehchi H, Eskandari-Yaghbastlo A, Pour Bahrami P, Elhami A, Faghihinia F, Nejati ST, et al. Exploring the role of oral bacteria in oral cancer: A narrative review. Discov Oncol. 2025;16(1):242. https://doi.org/10.1007/s12672-025-01998-2
23. Kim JY, Lee K, Lee MG, Kim SJ. Periodontitis and atherosclerotic cardiovascular disease. Mol Cells. 2024;47(12):100146. https://doi.
org/10.1016/j.mocell.2024.100146
24. Zhan Y, Jiao J, Jing W, Feng X, Tai B, Hu D, et al. Association between periodontitis and hypertension: Cross-sectional survey from the fourth national Oral Health survey of China (2015-2016). BMJ Open. 2023;13(3):e068724. https://doi.org/10.1136/bmjopen
-2022-068724
25. Larvin H, Kang J, Aggarwal VR, Pavitt S, Wu J. The additive effect of periodontitis with hypertension on risk of systemic disease and mortality. J Periodontol. 2022;93(7):1024-1035. https://doi.org/10
.1002/JPER.21-0621
26. Attiq A, Afzal S, Ahmad W, Kandeel M. Hegemony of inflammation in atherosclerosis and coronary artery disease. Eur J Pharmacol. 2024;966:176338. https://doi.org/10.1016/j.ejphar.2024.176338
27. Papi P, Pranno N, Di Murro B, Pompa G, Polimeni A, Letizia C, et al. Association between subclinical atherosclerosis and oral inflammation: A cross-sectional study. J Periodontol. 2023;94(4):477-486. https://doi.org/10.1002/JPER.22-0026
28. Curia MC, Pignatelli P, D'Antonio DL, D'Ardes D, Olmastroni E, Scorpiglione L, et al. Oral Porphyromonas gingivalis and Fusobacterium nucleatum abundance in subjects in primary and secondary cardiovascular prevention, with or without heterozygous familial hypercholesterolemia. Biomedicines. 2022;10(9):2144. https://doi.org/10.3390/biomedicines10092144
29. Li Z, Zhang R, Mu H, Zhang W, Zeng J, Li H, et al. Oral administration of branched-chain amino acids attenuates atherosclerosis by inhibiting the inflammatory response and regulating the gut microbiota in ApoE-deficient mice. Nutrients. 2022;14(23):5065. https://doi.org/10.3390/nu14235065
30. Zhang H, Zhang X, Yun Z, Chen Y, Cang S, Shao Y, et al. Loss of diurnal oscillatory rhythms in gut microbiota correlates with progression of atherosclerosis. Food Funct. 2025;16(9):3423-3438. https://doi.org/10.1039/D4FO05227G
31. Liu W, Wang J, Yang H, Li C, Lan W, Chen T, et al. The metabolite indole-3-acetic acid of Bacteroides ovatus improves atherosclerosis by restoring the polarisation balance of M1/M2 macrophages and inhibiting inflammation. Adv Sci (Weinh). 2025;12(11):e2413010. https://doi.org/10.1002/advs.202413010
32. Chiles R, Al-Horani RA. Vericiguat: A new hope for heart failure patients. Cardiovasc Ther. 2022;2022:1554875. https://doi.org/10.
1155/2022/1554875
33. Bezamat M. An updated review on the link between oral infections and atherosclerotic cardiovascular disease with focus on phenomics. Front Physiol. 2022;13:1101398. https://doi.org/10.3389/fphys.20
22.1101398
34. Snelson M, Muralitharan RR, Liu C-F, Markó L, Forslund SK, Marques FZ, et al. Gut-heart axis: The role of gut microbiota and metabolites in heart failure. Circ Res. 2025;136(11):1382-1406. https://doi.org/10.1161/CIRCRESAHA.125.325516
35. Kamde SP, Anjankar A. Pathogenesis, diagnosis, antimicrobial therapy, and management of infective endocarditis, and its complications. Cureus. 2022;14(9):e29182. https://doi.org/10.775
9/cureus.29182
36. Epprecht J, Ledergerber B, Frank M, Greutmann M, van Hemelrijck M, Ilcheva L, et al. Increase in oral streptococcal endocarditis among moderate-risk patients: Impact of guideline changes on endocarditis prevention. JACC Adv. 2024;3(10):101266. https://doi.org/10.101
6/j.jacadv.2024.101266
37. Kohil A, Abdalla W, Ibrahim WN, Al-Harbi KM, Al-Haidose A, Al-Asmakh M, et al. The immunomodulatory role of microbiota in rheumatic heart disease: What do we know and what can we learn from other rheumatic diseases? Medicina (Kaunas). 2023;59(9):1629. https://doi.org/10.3390/medicina59091629
38. Al-Jazairi A, Al-Jaser R, Al-Halees Z, Shahid M, Al-Jufan M, Al-Mayouf S, et al. Guidelines for the secondary prevention of rheumatic heart disease: Endorsed by Saudi Pediatric Infectious Diseases Society (SPIDS). Int J Pediatr Adolesc Med. 2017;4(1):47-50. https://doi.org/10.1016/j.ijpam.2017.02.002
39. Hirani K, Rwebembera J, Webb R, Beaton A, Kado J, Carapetis J, et al. Acute rheumatic fever. Lancet. 2025;405(10495):2164-2178. https://doi.org/10.1016/S0140-6736(25)00185-0
40. Pandian NG, Kim JK, Arias-Godinez JA, Marx GR, Michelena HI, Mohan JC, et al. Recommendations for the use of echocardiography in the evaluation of rheumatic heart disease: A report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2023;36(1):3-28. https://doi.org/10.1016/j.echo.2022.10.009
41. Matter MA, Paneni F, Libby P, Frantz S, Stähli BE, Templin C, et al. Inflammation in acute myocardial infarction: The good, the bad and the ugly. Eur Heart J. 2024;45(2):89-103. https://doi.org/10.1093/
eurheartj/ehad486
42. Rivera K, Gonzalez L, Bravo L, Manjarres L, Andia ME. The gut-heart axis: Molecular perspectives and implications for myocardial infarction. Int J Mol Sci. 2024;25(22):12465. https://doi.org/10.33
90/ijms252212465
43. Chen J, Zhu T, Yang J, Shen M, Wang D, Gu B, et al. Geniposide protects against myocardial infarction injury via the restoration in gut microbiota and gut-brain axis. J Cell Mol Med. 2025;29(3):e70406. https://doi.org/10.1111/jcmm.70406
44. Chen BY, Zhu H, Li YL, Zhang J, Xu S, Zhou LJ, et al. Oral pathobionts aggravate myocardial infarction through mobilization of B2 cells. Circulation. 2025;152(19):1348-1370. https://doi.org/10.
1161/CIRCULATIONAHA.125.074837
45. Zhu L, Liu Y, Wang K, Wang N. Regulated cell death in acute myocardial infarction: Molecular mechanisms and therapeutic implications. Ageing Res Rev. 2025;104:102629. https://doi.org/10
.1016/j.arr.2024.102629
46. Low JSY, Teh HF, Thevarajah TM, Chang SW, Khor SM. An AI-assisted microfluidic paper-based multiplexed surface-enhanced Raman scattering (SERS) biosensor with electrophoretic removal and electrical modulation for accurate acute myocardial infarction (AMI) diagnosis and prognosis. Biosens Bioelectron. 2025;270:116949. https://doi.org/10.1016/j.bios.2024.116949
47. Kucukakcali Z, Balikci Cicek I. Beyond black boxes: Interpretable AI with explainable neural networks (ENNs) for acute myocardial infarction (AMI) using common hematological parameters. Medicina (Kaunas). 2025;61(9):1552. https://doi.org/10.3390/med
icina61091552
48. Hernández-Ruiz P, Escalona-Montaño AR, Amezcua-Guerra LM, González-Pacheco H, Niccolai E, Amedei A, et al. Potential association of the oral microbiome with trimethylamine N-oxide quantification in Mexican patients with myocardial infarction. Mediators Inflamm. 2024;2024:3985731. https://doi.org/10.1155/
2024/3985731
49. Cho HJ, Shin MS, Song Y, Park SK, Park SM, Kim HD. Severe periodontal disease increases acute myocardial infarction and stroke: A 10-year retrospective follow-up study. J Dent Res. 2021;100(7):706-713. https://doi.org/10.1177/002203452098609
7
50. Sengupta PP, Kluin J, Lee SP, Oh JK, Smits AI. The future of valvular heart disease assessment and therapy. Lancet. 2024;403(10436):1590-1602. https://doi.org/10.1016/S0140-673
6(23)02754-X
51. Chioncel O, Adamo M, Nikolaou M, Parissis J, Mebazaa A, Yilmaz MB, et al. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. Eur J Heart Fail. 2023;25(7):1025-1048. https://doi.org/10.1002/e
jhf.2918
52. Yaguchi E, Komiyama Y, Inami S, Shibasaki I, Shintani T, Shiraishi R, et al. Oral dysbiosis is associated with the pathogenesis of aortic valve diseases. Microorganisms. 2025;13(7):1677. https://doi.org/1
0.3390/microorganisms13071677
53. Raffaelli L, Santangelo R, Falchetti P, Galluccio F, Luciani N, Anselmi A, et al. Examination of periodontal pathogens in stenotic valve specimens and in whole blood samples in patients affected by aortic valve stenosis and chronic periodontitis. Int J Immunopathol Pharmacol. 2010;23(2):561-566. https://doi.org/10.1177/0394632
01002300218
54. Nakano K, Inaba H, Nomura R, Nemoto H, Takeda M, Yoshioka H, et al. Detection of cariogenic Streptococcus mutans in extirpated heart valve and atheromatous plaque specimens. J Clin Microbiol. 2006;44(9):3313-3317. https://doi.org/10.1128/jcm.00377-06
Veröffentlicht
Versionen
- 2025-12-20 (2)
- 2025-12-20 (1)
Ausgabe
Rubrik
Lizenz
Copyright (c) 2026 Gamal A. Atia (Author)
Dieses Werk steht unter der Lizenz Creative Commons Namensnennung - Nicht-kommerziell 4.0 International.
